Linked Life Data

15219195

Source:http://linkedlifedata.com/resource/pubmed/id/15219195

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2004-6-28
pubmed:abstractText
Circulating procoagulant microparticles (MP) were measured as markers of vascular damage and prothrombotic risk in patients undergoing ST-segment myocardial infarction (STEMI) treated by primary percutaneous transluminal coronary angioplasty (PTCA) and additional GPIIb-IIIa antagonists. Cells possibly more responsive to GPIIb-IIIa (alpha(IIb)beta(3)) antagonists were evidenced through MP phenotypes by comparison with healthy volunteers (HV) and STEMI patients treated by PTCA without GPIIb-IIIa antagonist (CP). In 50 STEMI patients, blood samples were collected at day 1 and day 6. Circulating procoagulant MP were captured on annexin V and quantified by prothrombinase assay as nanomolar phosphatidylserine equivalents (nm PhtdSer). Platelet activation by thrombin was confirmed through independent measurement of soluble GPV (sGPV). With respect to HV, procoagulant MP levels were high in patients with STEMI or unstable angina, platelet-derived MP and elevated sGPV testifying to significant platelet activation. A substantial release of endothelial-derived MP was evidenced simultaneously. In abciximab-treated patients, procoagulant MP, mainly of platelet origin, decreased precociously at day 1 (4.2 +/- 0.6 vs. CP 15.5 +/- 2.1 nm PhtdSer; P = 0.001) together with sGPV (36 +/- 3 vs. CP 58 +/- 8 ng mL(-1); P = 0.02). Leukocyte-derived MP decreased at day 6 (0.12 +/- 0.04 vs. CP 0.56 +/- 0.12 nm PhtdSer; P = 0.01) suggesting a possible effect on underlying inflammatory status. In patients presenting cardiovascular events at 6-month follow-up, procoagulant MP levels at day 1 could be indicative of a worsened outcome. MP could constitute a relevant parameter for the follow-up of STEMI patients treated by GPIIb-IIIa antagonists.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1538-7933
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1118-26
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:15219195-Adrenergic beta-Antagonists, pubmed-meshheading:15219195-Adult, pubmed-meshheading:15219195-Aged, pubmed-meshheading:15219195-Angioplasty, Balloon, Coronary, pubmed-meshheading:15219195-Antibodies, Monoclonal, pubmed-meshheading:15219195-Aspirin, pubmed-meshheading:15219195-Biological Markers, pubmed-meshheading:15219195-Female, pubmed-meshheading:15219195-Follow-Up Studies, pubmed-meshheading:15219195-Humans, pubmed-meshheading:15219195-Immunoglobulin Fab Fragments, pubmed-meshheading:15219195-Male, pubmed-meshheading:15219195-Middle Aged, pubmed-meshheading:15219195-Myocardial Infarction, pubmed-meshheading:15219195-Particle Size, pubmed-meshheading:15219195-Platelet Aggregation Inhibitors, pubmed-meshheading:15219195-Platelet Glycoprotein GPIIb-IIIa Complex, pubmed-meshheading:15219195-Platelet Glycoprotein GPIb-IX Complex, pubmed-meshheading:15219195-Predictive Value of Tests, pubmed-meshheading:15219195-Prognosis, pubmed-meshheading:15219195-Solubility, pubmed-meshheading:15219195-Thrombophilia
pubmed:year
2004
pubmed:articleTitle
Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists.
pubmed:affiliation
Fédération de Cardiologie des Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial